Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03145064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03145064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2017
Completion date
September 3, 2020
Enrollment
41 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma